Integrative Enzymatics

Integrative Enzymatics is a biotechnology company dedicated to developing structure-based pharmaceutical products to treat chronic metabolic disorders. The company’s primary offering is an intellectual property portfolio that consists of two drugs used for the treatment of Type I Diabetes Mellitus and Type II Diabetes Mellitus. The efficacy of both pharmaceuticals have been demonstrated in silico, in vitro, and verified through pilot animal studies. Second round animal trials are ongoing. Integrative Enzymatics has developed a proprietary method of designing pharmaceuticals. Their flagship patented drug treats diabetes.